Global Sepsis Diagnostics Industry Aims for Spectacular 8.1% CAGR, Targets Surpassing US$ 1.2 Billion by 2033 | Reports FMI

The Global Sepsis Diagnostics Industry is on the brink of an unprecedented growth phase, with a projected Compound Annual Growth Rate (CAGR) of 8.1% between 2023 and 2033. Valued at US$ 561.2 million in 2023, the market is anticipated to soar beyond US$ 1.2 billion by the close of 2033.

This significant expansion is fueled by a confluence of factors driving demand for sepsis diagnostics. The escalating prevalence of antibiotic-resistant bacterial strains, a steadily aging global population, and an upswing in hospital-acquired infections have intensified the need for advanced diagnostic solutions. Notably, the surge in product approvals for sepsis diagnosis is expected to further propel the demand for cutting-edge diagnostics within the sector.

Despite the optimistic trajectory, the industry faces challenges that warrant attention. The shortage of experienced specialists for sepsis diagnosis poses a notable obstacle, compounded by a lack of awareness and the persistent reliance on conventional processes during antibiotic production, all identified as factors impacting the sales of sepsis diagnostics.

However, the market’s potential is buoyed by positive indicators in developing markets. The increasing incidence of newborn umbilical cord infections and a rise in surgical procedures in these regions provide a favorable landscape for the growth of sepsis diagnostics.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-14272

HAIs, also known as nosocomial infections, are a leading source of morbidity and mortality in hospitals around the world. Urinary tract infections, pneumonia, and sepsis are the most frequent hospital-acquired infections (HAIs). In addition, in immunocompromised individuals, aged patients, and people with chronic conditions, HAIs can cause sepsis. Because of the significant rise in HAIs around the world, demand for sepsis diagnostic devices is projected to expand in the future years.

Sepsis is a complex condition to detect, and even a one-minute delay in antibiotic delivery increases the chance of death by 7.6% in septic shock patients with hypertension. As a result of the emerging trends in the Global Sepsis Diagnostics Industry, there is a greater need for quick sepsis detection to avoid antibiotic therapy delays in sepsis patients.

Many sepsis diagnostic companies are growing their product offerings in point-of-care technologies, which can quickly identify sepsis, cut down on diagnosis time, and improve life expectancy after sepsis.

Key Takeaways from the Global Sepsis Diagnostics Industry

• Attributed to the presence of a larger consumer population in developing markets such as India and China, the Asia Pacific region of rapid sepsis diagnostics is expected to grow profitably over the forecast period.
• The Global Sepsis Diagnostics Market adoption trends indicate North America is likely to generate more than $200 million in revenue by the end of 2026. The sepsis diagnostics companies in the region are growing due to well-established healthcare infrastructure and increased usage of innovative products. Septic poisoning is also one of the leading causes of death in the United States.
• As per the sepsis diagnostics market analysis, microbiology technology is likely to gain traction. Microbiology is expected to generate more than $200 million in income by 2026.
• By product, the sepsis diagnostics market opportunities are divided into blood culture media, assays & reagent kits, devices, and software. The blood culture media segment held the most significant market share during the forecast period. This growth can be ascribed to a rise in blood culture media as a sepsis diagnostics device.

Reach Out to Our Analyst For Your Queries
https://www.futuremarketinsights.com/ask-question/rep-gb-14272

“Sepsis diagnostics devices are expensive, limiting the growth of this industry. Additionally, in certain countries, there are no clear guidelines for the treatment of sepsis, and there is a lack of awareness about the repercussions of sepsis if it is not treated effectively.”

Competitive Landscape Organizations in the global quality articulation market are consolidating and acquiring systems to gain a competitive advantage and generate significant profits. On the other hand, some players benefit from significant new work systems to gain a competitive advantage in the Global Sepsis Diagnostics Industry statistics.

• Cytovale Inc. and the Biomedical Advanced Research and Development Authority, or BARDA, announced cooperation in April 2020 to increase the use of Cytovale’s Rapid Sepsis Diagnostic System for identifying sepsis in patients with probable respiratory infections, such as COVID-19.
• Immunexpress announced a quick SeptiCyte, a one-hour molecular diagnostic test for sepsis, on Biocartis’ Idylla platform in Europe in October 2020. This is one of the first deeply integrated, immune response-based diagnostics to help clinicians diagnose sepsis and Global Sepsis Diagnostics Industry analysis.

Global Sepsis Diagnostics Industry Key Segments

By Product:

• Blood Culture Media
• Assays & Reagents
• Instruments, and Software

By Technology:

• Blood Culture
• Immunoassays
• Molecular Diagnostics
• Flow Cytometry
• Microfluidics
• Biomarkers

By Method:

• Automated Diagnostics
• Conventional Diagnostics

By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis
• Others

By Test Type:

• Laboratory Tests
• Point-of-Care Tests

By End User:

• Hospitals and Specialty Clinics
• Pathology & Reference Laboratories
• Research Laboratories & Academic Institutes

Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/14272

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube